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Introduction
FGF receptors (FGFRs), as members of the receptor tyrosine 
kinase (RTK) family, are known to signal, after ligand binding and 
receptor dimerization, from the cell membrane as well as from 
endosomal compartments (Sorokin et al., 1994; Eswarakumar 
et al., 2005; Kermorgant and Parker, 2008). Signal transduction, 
primarily through the MAPK pathway but also acting via 
phosphoinositide 3-kinase (PI3K), PLC-, and STATs (Corson 
et al., 2003; Dailey et al., 2005), results in activation of several 
known target genes (e.g., CyclinD1 and PEA3) to modulate 
cell behavior (Ho and Dowdy, 2002; Chioni and Grose, 2009). 
In addition to these well-studied signaling pathways, there is a 
growing body of evidence showing that full-length FGFRs, 
and FGFR1 in particular, can be targeted to the nucleus (Maher, 
1996; Stachowiak et al., 1996a,b; Peng et al., 2001, 2002; Hu 
et al., 2004; Bryant et al., 2005). Relatively few studies have 
addressed the mechanism by which full-length RTKs trans-
locate from the cell membrane to the nucleus (Stachowiak 
et al., 1996a, 2007; Reilly and Maher, 2001; Peng et al., 
2002; Hu et al., 2004; Reilly et al., 2004); however, there is 
a model emerging whereby, upon ligand binding, activated 
receptors are internalized to the early endosome compartment 
(Bryant and Stow, 2005; Bryant et al., 2005). Although FGF 
ligands are known to exit the endosome by a mechanism depen-
dent on vesicular transmembrane potential (Małecki et al., 
2002), how the receptors escape is unclear. Once in the cyto-
plasm, full-length FGFR1 has been shown to use the Importin  
pathway to enter the nucleus (Reilly and Maher, 2001), where 
the receptor can interact with nuclear proteins to regulate tran-
scription (Wiedłocha et al., 1994; Hu et al., 2004).
An alternative, and more intuitive, model for the nuclear 
trafficking of receptors is that activation-dependent cleavage 
of the intracellular domain allows the free cytoplasmic portion 
to translocate to the nucleus without a full-length receptor 
having to extract itself from the lipid bilayer. This mecha-
nism is well known for Notch signaling (Bray, 2006) but has 
been shown for other receptors; these include ErbB4, which 
also undergoes ADAM-mediated ectodomain cleavage before 
-secretase cleavage and subsequent nuclear translocation 
(Carpenter and Liao, 2009). However, to date, there are no 
data suggesting that a similar proteolytic pathway might play 
a role in FGFR signaling, although, interestingly, FGFR1 has 
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(in serum-free medium) increased cell number significantly in 
MCF-7 cells only after 48 h. However, there was no change 
in cell number with any of the treatments during the course 
of the Transwell migration assays. Cells were stained with 
an anti-Ki67 antibody to quantify cell proliferation. FGF-10 
treatment resulted in a significant increase, after 48 h, in the 
percentage of MCF-7 cells staining positive for the prolifera-
tion marker Ki67 (Fig. 1 C). Moreover, FGF-10 treatment 
reduced apoptosis in MCF-7 cells after 48 h as determined 
by TUNEL assay (Fig. 1 D).
Subcellular localization of FGFR1
FGF-10 treatment (60 min) of serum-starved MCF-7 and MDA-
MB-231 cells resulted in dramatically increased nuclear local-
ization of FGFR1 immunostaining (Fig. 2 A and Fig. S1 A). 
This effect was abolished in the presence of the PD173074 
inhibitor (Fig. 2 A); hence, the phenomenon was FGFR signaling 
specific. The results were reproduced independently (Fig. S1 A) 
using anti-FGFR1 antibodies specific for the C terminus and 
juxtamembrane regions of human FGFR1 (Santa Cruz Biotech-
nology, Inc. and Abcam, respectively). A z scan of images taken 
with both anti-FGFR1 antibodies showed that FGFR1 was within 
the nucleus (Fig. 2 A and Fig. S1 B).
To validate the antibodies used for detecting FGFR1 in 
immunofluorescence and Western blotting, we knocked 
down FGFR1 expression using RNAi (Fig. S1, C and D). 
MCF-7 and MDA-MB-231 cells, treated with a scrambled 
RNAi control or FGFR1-specific RNAi, showed significantly 
reduced FGFR1 mRNA expression as determined by real-
time RT-PCR (Fig. S1 C). This knockdown of expression 
also was evident at the protein level, with control MCF-7 
cells showing clear staining for FGFR1, in contrast to the 
absence of staining in cells treated with FGFR1 RNAi (Fig. S1 D). 
In addition, Western blotting also detected a significant reduc-
tion of FGFR1 after RNAi treatment (Fig. S1 D). The FGFR1 
signal in Western blotting was eliminated by preincubation 
with an immunizing peptide (unpublished data).
To confirm immunofluorescence findings, subcellular 
fractionation and Western blotting on MCF-7 cells were per-
formed after FGF-10 stimulation. Four fractions were 
obtained (cytoplasm, plasma membrane/organelles, nucleus, 
and cytoskeleton), revealing full-length FGFR1 (120 kD) 
in the plasma membrane/organelle fraction and a truncated 
FGFR1 fragment (55–60 kD) in the nuclear fraction 
(Fig. 2 B). Both the nuclear FGFR1 and full-length FGFR1 
bands disappeared after preincubation of the anti-FGFR1 
antibody with the immunizing peptide (unpublished data). 
FGF-10 stimulation of MCF-7 cells (0–60 min) caused a sig-
nificant increase in accumulation of the truncated 55-kD 
C-terminal fragment of FGFR1 in the nuclear fraction (Fig. 2 B). 
Normalization to the nuclear marker TOPOIIa highlighted 
the significance of the nuclear FGFR1 accumulation (Fig. 2 B, 
graph). Immunoblotting with TOPOIIa and BIP antibodies 
confirmed the specificity of the cell fractionation protocol, 
and pERK confirmed successful FGF-10 stimulation (Fig. 2 B). 
Similar results were obtained with MDA-MB-231 cells 
(unpublished data).
been identified previously as a substrate for Granzyme B 
(GrB)–mediated cleavage (Loeb et al., 2006).
With evidence increasing that other RTKs play a func-
tional role in the nucleus (Wang et al., 2010), we show here, 
for the first time, that a C-terminal fragment of FGFR1, gen-
erated by receptor activation-dependent cleavage, traffics to 
the nucleus and regulates the expression of target genes. We 
confirm GrB as the protease that mediates cleavage and show 
that GrB inhibition can block specific FGF-dependent effects 
on cancer cells. Having identified a functional role for nu-
clear FGFR1 in 2D and 3D cell culture models, we show that 
this phenomenon also occurs in vivo in invasive breast can-
cer and have identified a panel of FGFR1-regulated target 
genes, all of which regulate cell migration and thus could 
reflect an invasive signature.
The FGFR signaling pathway is implicated in a wide 
range of pathologies, most notably cancer (Turner and Grose, 
2010), yet its efficient targeting is proving challenging to the 
pharmaceutical industry, partly because FGFR signaling is 
fundamental to so many normal biological processes. Our data 
suggest that targeting GrB rather than FGFR1 might represent 
a novel therapeutic approach in blocking cancer invasion.
Results
Expression and activation of FGFR1 and its 
biochemical and functional consequences
To ensure that our breast cancer cell lines exhibited a stan-
dard response to FGF-10 stimulation, serum-starved MCF-7 
cells were stimulated with 100 ng/ml FGF-10 in the presence 
of 300 ng/ml heparin in serum-free media for 15, 30, and 
60 min. Western blotting using antibodies specific to phosphory-
lated FRS2, extracellular signal–regulated kinase (ERK), 
AKT, and PLC- confirmed that stimulation with FGF-10 
activated the FRS2 ERK pathway as well as the AKT path-
way in MCF-7 cells (Fig. 1 A). FGF-10 treatment triggered 
rapid ERK phosphorylation, and this response was blocked 
by pretreatment with the FGFR inhibitor, PD173074 (2 µM; 
1 h; Fig. 1 A). Other pathways (PLC- and PI3K) were in-
vestigated also, but although FGF-10 induced AKT phos-
phorylation, this was only partially reduced by treatment 
with PD173074 (Fig. 1 A).
To confirm that our cell lines behaved as expected after 
FGF-10 treatment, we performed a series of functional assays. 
Migration of MCF-7 and MDA-MB-231 cells was monitored 
using 8-µm-pore Transwell migration filters in a 24-well plate 
format overnight in serum-free medium in the presence or 
absence of FGF-10/heparin and/or PD173074 (Fig. 1 B). FGF-10 
treatment increased Transwell migration of both MCF-7 and 
MDA-MB-231 cells significantly, and this effect was blocked 
in the presence of PD173074 (Fig. 1 B).
To confirm that the effect of FGF-10 on migration was a 
result of more cells migrating through the Transwell mem-
brane and not caused by cell proliferation and/or cell death, 
cells were plated in 24-well plates in serum-free media (with 
or without FGF-10/heparin and/or PD173074) and counted 
after 12, 24, and 48 h (unpublished data). FGF-10 treatment 
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decreased nuclear FGFR1 staining (Fig. 3 B). Western blot analysis 
also showed that 72-h treatment with RNAi to GrB reduced levels 
of nuclear FGFR1, despite an overall increase in full-length FGFR1 
(Fig. 3 C). Efficiency of GrB knockdown was analyzed both by 
immunofluorescence and Western blotting (Fig. 3, B and C).
Subcellular fractionation and confocal analysis revealed 
that, similar to GrB RNAi, treatment with a GrB inhibitor blocked 
the capacity of FGF-10 to induce nuclear localization of FGFR1 
Cleavage of FGFR1 by GrB
FGFR1 previously has been identified as a substrate for GrB 
(Loeb et al., 2006), and a schematic representation of FGFR1 
depicting the GrB cleavage site at Asp-432 is shown (Fig. 3 A). 
Western blot analysis with an anti-GrB antibody confirmed GrB 
expression in MCF-7 cells (Fig. 3).
Confocal analysis of MCF-7 cells treated with GrB RNAi 
for 72 h revealed efficient knockdown of GrB, concomitant with 
Figure 1. Cell signaling pathways activated upon FGF-10 stimulation and their impact on cell behavior. (A) Serum-starved MCF-7 cells were stimulated with 
100 ng/ml FGF-10 in the presence of 7.5 µg/ml heparin in serum-free media for 15, 30, and 60 min. Where indicated, cells were pretreated with 2 µM 
PD173074 (1 h). Cell lysates were prepared, and Western blotting was performed using different primary antibodies. Stimulation with FGF-10 activated the 
FRS2–ERK pathway as well as the AKT pathway. FGF-10 treatment triggered rapid ERK phosphorylation, which was blocked by the FGFR inhibitor PD173074. 
Other pathways (PLC- and PI3K) were also investigated, but although FGF-10 induced AKT phosphorylation, this was not abrogated by treatment with 
PD173074. PLC- was not activated by FGF-10 treatment. (B) Migration of MCF-7 and MDA-MB-231 cells was monitored using 8-µm-pore Transwell migration 
filters in serum-free medium in the presence of FGF-10/heparin (100 ng/ml and 7.5 µg/ml, respectively) and/or 2 µM PD173074. Cells were allowed to 
migrate overnight. FGF-10 treatment increased Transwell migration significantly, and this effect was blocked in the presence of the PD173074. (C) Immuno-
staining with an anti-Ki67 antibody to quantify cell proliferation after 48 h revealed that treatment with FGF-10 resulted in a significant increase in the percent-
age of positive cell staining. (D) FGF-10 treatment reduced apoptosis in MCF-7 cells after 48-h treatment with FGF-10, as determined by TUNEL assay (PI, 
propidium iodide). *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001 (ANOVA for B; Student’s t test for C and D). Bars, 25 µm. Error bars show means ± SEM.
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To demonstrate direct GrB activity in MCF-7 cell 
lysates, we performed GrB activity assays using a chromogenic 
substrate, Ac-IEPD-pNA (Fig. 4, E and F; and Fig. S3). The 
efficacy of the assay was confirmed using human recombinant 
GrB as a positive control, with increasing concentrations of 
recombinant GrB producing increasing signals (Fig. S3 A). 
Furthermore, we confirmed the inhibition of recombinant GrB 
activity by 3,4-dichloroisocouramin (DCI; an inhibitor of serine 
proteases) upon inclusion of the inhibitor (50 µM) in the reac-
tion mix (Fig. S3 B). Lysates from serum-starved MCF-7 cells 
treated for 1 h with FGF-10 showed significantly increased 
GrB activity, as measured hourly after incubation for 0–4 h 
with the chromogenic substrate Ac-IEPD-pNA (Fig. 4 E). 
Similarly, 15-min treatment with FGF-10 was sufficient to 
increase GrB activity but only after 3-h incubation with the 
Ac-IEPD-pNA substrate (Fig. S3 C). Importantly, pretreatment 
(Fig. 4, A–C). MCF-7 cells growing in complete medium were 
treated with 25 and 50 µM GrB inhibitor for 6, 12, 24, and 48 h 
(Fig. S2 A). No change in nuclear FGFR1 localization was 
observed after 6 h of treatment. However, treatment with GrB 
inhibitor abolished nuclear FGFR1 after 24 h without changing 
the total FGFR1 protein levels (Fig. 4 C). The effect was apparent 
after 12 h of treatment and sustained up to ≥48 h (Fig. S2 A).
To confirm that GrB inhibition could block FGF-10–induced 
migration, we performed Transwell migration assays on MCF-7 
cells in the presence or absence of GrB inhibitor and FGF-10 
(Fig. 4 D). GrB inhibition completely and specifically blocked 
FGF-10–induced migration. Although inhibitor-treated cells 
clearly migrated less than control unstimulated cells, they still 
were capable of mounting a significant migratory response to 
EGF (Fig. 4 D). This effect also was observed when MCF-7 
cells were treated with RNAi to GrB (Fig. S2, B and C).
Figure 2. Subcellular localization of FGFR1 in 2D culture. (A) FGF-10 stimulation (60 min) resulted in increased nuclear FGFR1 localization in serum-
starved MCF-7 cells, confirmed by examining confocal z-stack sections. The effect was abolished in the presence of PD173074. The green, purple, and 
red boxes represent the x-z and y-z scan perspectives from the confocal z stack. Bars, 25 µm. (B) Subcellular fractionation revealed that FGF-10 treatment 
increased nuclear FGFR1 localization in MCF-7 cells. Over a time course of FGF-10 stimulation (0–60 min), there was a significant increase in accumulation 
of a truncated 55-kD C-terminal fragment of FGFR1 in the nuclear fraction (highlighted in black box), but there was no change in full-length FGFR1 levels. 
Immunoblotting with anti-TOPOIIa and anti-BIP antibodies confirmed the specificity of the cell fractionation protocol, and pERK confirmed the efficiency of 
FGF-10 stimulation. Nuclear FGFR1 was normalized to the nuclear marker TOPOIIa, confirming the significance of the accumulation (graph; *, P ≤ 0.05; 
**, P ≤ 0.01 [Student’s t test]). Error bars show means ± SEM. A.U., arbitrary unit; PM, plasma membrane.
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analysis revealed that, 48 h after transient transfection, MCF-7 
cells with wild-type (WT) FGFR1b (VSAD) expressed high 
levels of both full-length and nuclear FGFR1 compared with 
empty vector–transfected control cells. Cells transfected with 
mutant FGFR1b (VSAN) expressed higher levels of full-length 
FGFR1 compared with control-transfected cells (pcDNA4/TO) 
but did not show high levels of nuclear FGFR1 (Fig. 5 B). The 
functional relevance of this finding was tested using Transwell 
with DCI before FGF-10 treatment blocked the induction of 
GrB activity (Fig. 4 E). Furthermore, 50 µM DCI treatment 
(5 h) of MCF-7 cells growing in complete medium resulted 
in a significant decrease in both GrB activity (Fig. 4 F) and 
in cleaved nuclear FGFR1 protein (Fig. 4 G).
The mechanism of FGFR1 cleavage by GrB was investi-
gated by mutating the GrB cleavage site within FGFR1b as 
described previously (Fig. 5 A; Loeb et al., 2006). Confocal 
Figure 3. Inhibition of GrB by RNAi in MCF-7 cells reduced nuclear FGFR1 accumulation. (A) Schematic representation of FGFR1 depicting the three 
IgG loops of the extracellular domain, the transmembrane region (TM), and the split tyrosine kinase domain. The arrow indicates GrB cleavage site at 
Asp-432. Numbers indicate amino acid residues. Adapted from Loeb et al. (2006). N, N terminus; C, C terminus. (B) Treatment of MCF-7 cells, grow-
ing in serum-containing medium, with a GrB inhibitor abolished nuclear FGFR1 after 24 h but did not change the total FGFR1 protein levels. Confocal 
analysis of MCF-7 cells growing in serum-containing medium treated with GrB RNAi for 72 h revealed efficient knockdown of GrB concomitant with 
decreased nuclear FGFR1 staining. **, P < 0.01; ***, P < 0.001 (Student’s t test). Bar, 25 µm. (C) Western blot analysis confirmed that GrB was 
expressed in MCF-7 cells and showed that 72-h treatment with RNAi to GrB reduced levels of nuclear FGFR1, despite an overall increase in full-length 
FGFR1. *, P < 0.05; **, P < 0.01 (Mann–Whitney test). Error bars show means ± SEM. A.U., arbitrary unit; Ctr, control.
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Figure 4. Treatment of MCF-7 cells with a GrB inhibitor reduced nuclear FGFR1 accumulation and blocked FGF-10–dependent cell migration. (A) Treatment 
of MCF-7 cells, growing in serum-containing medium, with a GrB inhibitor (inh.) abolished nuclear FGFR1 (arrows) after 24 h but did not change the total 
FGFR1 protein levels. *, P < 0.05 (ANOVA). Bar, 100 µm. (B) Subcellular fractionation confirmed that FGF-10 treatment (1–2 h) increased nuclear FGFR1 
(a truncated 55-kD C-terminal fragment of FGFR1) in serum-starved MCF-7 cells and decreased it when cells were treated with 25 µM GrB inhibitor (24 h). 
When cells were pretreated with GrB inhibitor and then treated with FGF-10, the translocation of the nuclear FGFR1 was partially blocked. Immunoblotting 
with Lamin A/C and tubulin antibodies confirmed the specificity of the cell fractionation protocol. Nuclear FGFR1 was normalized to the nuclear marker 
Lamin A/C, confirming the significance of the accumulation (graph). (C) MCF-7 cells were treated with 25 µM GrB inhibitor (24 h) in serum-free medium 
before stimulation with FGF-10/heparin (100 ng/ml and 7.5 µg/ml, respectively). Control cells showed increased staining for nuclear FGFR1 (arrows) 
after FGF-10 treatment, and this was blocked by GrB inhibition. Bar, 25 µm. (D) Transwell migration assays with MCF-7 cells showed that GrB inhibition 
abolished the promigratory effect of FGF-10. In contrast, cells were still able to migrate in response to EGF stimulation. *, P ≤ 0.05; **, P ≤ 0.01 (Student’s 
t test). (E) GrB activity in lysates from serum-starved MCF-7 cells with or without FGF-10/heparin treatment (100 ng/ml and 7.5 µg/ml, respectively) in the 
presence or absence of pretreatment with the serine protease inhibitor 3,4-dichloroisocoumarin (DCI; 50 µM; 1-h pretreatment). Activity was measured at 
405-nm absorbance at hourly intervals after the addition of 200 µM Ac-IEPD-pNA substrate. FGF-10 treatment significantly increased GrB activity in MCF-7 
cells, but this effect was abrogated by pretreatment with DCI. **, P ≤ 0.01; ***, P ≤ 0.001 (Student’s t test). (F) GrB activity in MCF-7 cells growing 
in full serum is markedly reduced by treatment with 50 µM DCI (2 h). (G) 5-h treatment with 50 µM DCI decreased nuclear FGFR1 protein significantly. 
*, P ≤ 0.05 (Student’s t test). Error bars show means ± SEM. A.U., arbitrary unit; Ctr, control.
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compared with empty vector–transfected control cells. How-
ever, in the presence of GrB inhibitor, the promigratory effect 
of the full-length receptor was abrogated, whereas cells ex-
pressing IC-FGFR1-MYC still showed significantly enhanced 
migration (Fig. 6 B).
How GrB is activated after FGF-10 stimulation is the sub-
ject of ongoing experiments in the laboratory. Initial observations 
revealed that, immediately after FGF-10 stimulation of serum-
starved MCF-7 cells, there was a clear increase in expression 
and processing of Cathepsin C (Fig. S4 A), concomitant with an 
increase in GrB protein levels.
Nuclear localization of FGFR1 in 3D culture 
and in vivo
Because FGFR1 localized to the nucleus specifically in breast 
cancer cells stimulated with FGF-10, we used an organotypic 
model to investigate the phenomenon in a more physiological 
migration assays (Fig. 5 C). Under control conditions (unstimu-
lated cells), MCF-7 cells transfected with WT FGFR1b (VSAD) 
migrated significantly more than empty vector (pcDNA4/TO)– or 
mutant FGFR1b (VSAN)–transfected cells. Importantly, FGF-10 
stimulation increased cell migration in MCF-7 cells transfected 
with WT FGFR1b (VSAD) or empty vector (pcDNA4/TO) but 
did not have an effect on MCF-7 cells transfected with mutant 
FGFR1b (VSAN).
To investigate further the potential role of the cleaved 
intracellular fragment (IC) of FGFR1, we cloned the cDNA 
encoding the C-terminal cleaved portion into an expression 
vector, pcDNA4/TO, adding a C-terminal MYC epitope tag 
(Fig. 6 A). Efficient expression of the construct after tran-
sient transfection into MCF-7 cells was determined by West-
ern blotting and immunofluorescence (Fig. 6 A). Expression 
either of full-length FGFR1 or IC-FGFR1-MYC in MCF-7 
cells resulted in significantly increased Transwell migration 
Figure 5. Mutation of GrB cleavage site inhibited nuclear translocation of FGFR1. (A) Site-directed mutagenesis on wild-type (WT) FGFR1 changed the 
guanine nucleotide at position 1963 to adenine (g1963a; using sequence available from GenBank/EMBL/DDBJ under accession no. NM_023106.2) 
and thereby amino acid 432 from aspartic acid to alanine (D432N), abolishing the GrB cleavage site in Mutant FGFR1. (B) Confocal analysis of MCF-7 
cells transiently transfected (48 h) with WT (VSAD) or mutant (VSAN) FGFR1b revealed that mutant (VSAN) FGFR1b did not translocate to the nucleus. 
Bar, 50 µm. (C) Transwell migration assays showed that, under control conditions, MCF-7 cells transfected with WT FGFR1b (VSAD) migrated more 
compared with empty vector (pcDNA4/TO)– and mutant FGFR1b (VSAN)–transfected cells. FGF-10 stimulation increased migration in cells transfected 
with WT FGFR1b (VSAD) but did not affect MCF-7 cells transfected with mutant FGFR1b (VSAN). *, P ≤ 0.05 (paired Student’s t test and ANOVA). 
Error bars show means ± SEM.
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Chioni et al., 2005) showed that the invading cells formed dis-
tinct groups within the stroma (Fig. 7 D and Video 1). Ki67 
staining of transverse sections from the OC revealed that cell 
proliferation was restricted to invading cells and not those 
cells that have remained at the air–liquid interface (Fig. 7 E). 
A breast cancer OC growing for 10 d in the presence of the 
PD173074 inhibitor showed significantly less cancer cell inva-
sion compared with controls, as judged by quantification of 
their invasion index (Fig. 7, F and G). Immunohistochemical 
and immunofluorescent staining of tissues from breast cancer 
patients with an anti-FGFR1 antibody revealed specific FGFR1 
staining in the myoepithelial compartment of ductal carci-
noma in situ, and even stronger staining was detected in inva-
sive carcinoma, including nuclear staining in some invading 
cells (Fig. 7, H and I).
microenvironment. The organotypic culture (OC) consisted of a 
collagen/Matrigel mix containing human foreskin fibroblasts, 
as the stromal equivalent, overlaid with MDA-MB-231 cells 
(Fig. 7 A; Chioni and Grose, 2008). The OC was raised to an 
air–liquid interface and cultured for 10 d before fixation. Hema-
toxylin and eosin staining revealed invading particles (group 
of cells) within the stroma (Fig. 7 B). Staining of the OC with 
anti–FGF-10 and anti-FGFR1 antibodies showed that FGF-10 
was expressed highly both in invading and noninvading cells 
(Fig. 7 C). However, FGFR1 was localized mainly to the nu-
cleus in invading cells, whereas in the noninvading cells, it was 
mainly in the plasma membrane and cytoplasm (Fig. 7 C). Still 
images and videos obtained by optical projection tomography 
on OCs stained with the neonatal voltage-gated sodium channel 
(NESO) antibody (a marker for metastatic breast cancer cells; 
Figure 6. Expression of the intracellular domain 
of FGFR1 in MCF-7 cells increased cell migra-
tion and bypassed GrB inhibition. (A) West-
ern blotting confirmed successful transfection 
of the intracellular C-terminal FGFR1 (IC-
FGFR1-MYC) fragment in MCF-7 cells. A 55-
kD band was present with both anti-FGFR1 
antibody or an anti–c-MYC antibody. Simi-
larly, immunofluorescence showed enhanced 
nuclear FGFR1 in the cells transfected with 
the IC-FGFR1-MYC construct. Bar, 25 µm. 
(B) Transwell migration assays showed that, under 
control conditions, MCF-7 cells transfected with 
both full-length FGFR1b and IC-FGFR1-MYC 
migrated more compared with empty vector 
(pcDNA4/TO) cells. GrB inhibition decreased 
migration in all cells transfected with empty 
vector, full-length (FL) FGFR1b, or IC-FGFR1-
MYC compared with untreated cells, but there 
was a significant difference in the cells trans-
fected with IC-FGFR1-MYC compared with 
empty vector, whether or not there was no 
difference between cell transfected with full-
length FGFR1b. *, P ≤ 0.05; **, P < 0.01; 
***, P < 0.001 (paired Student’s t test and 
ANOVA). Error bars show means ± SEM.
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Figure 7. FGFR1 localizes to the nucleus in invading cells in 3D culture and in vivo. (A) A breast cancer organotypic model was designed using a col-
lagen/Matrigel mix containing human foreskin fibroblasts as the stromal equivalent, overlaid with MDA-MB-231 cells. OCs were raised into an air–liquid 
interface and cultured for 10 d before fixation in 4% PFA. (B) Hematoxylin and eosin staining revealed invading particles (group of cells) in the stroma. 
(C) FGF-10 was highly expressed in both invading and noninvading cells. FGFR1 was localized mainly to the nucleus (DAPI stain) of invading cells and 
remained mainly in the plasma membrane and cytoplasm of noninvading cells. (D) Still optical projection tomography image of an OC stained with NESO 
antibody, a marker for metastatic breast cancer cells (Chioni et al., 2005), highlighted that the invading cells formed distinct groups within the stroma 
(Video 1). (E) Anti-Ki67 staining of transverse sections from OCs revealed that cell proliferation was restricted to invading cells and not those cells that 
remained at the air–liquid interface. (F and G) Breast cancer OCs growing for 10 d in the presence of PD173074 showed significantly less cancer cell 
invasion compared with control. The invasion index comprises the combined measurements of (a) depth of invasion (mean of several measurements from 
each OC, taken from the top layer of the noninvading cells to the middle of the invading particles). (b) number of invading particles, and (c) mean area 
of the invading particles (n = 4 OCs for each condition). Error bars show means ± SEM. (H) Immunohistochemistry of human tissues from patients with an 
anti-FGFR1 antibody revealed that, although the IgG negative control remained clear for brown DAB staining (left), specific FGFR1 staining was detected in 
the myoepithelial compartment of ductal carcinoma in situ (arrows in middle image) and even stronger staining was detected in invasive lobular carcinoma 
(arrows in right image), including nuclear staining in some invading cells (B). This is shown by confocal sectioning of immunofluorescently stained invasive 
carcinoma, in which FGFR1 (green) can be seen in the nuclei (red) as labeled by open arrows (colocalization in yellow). **, P ≤ 0.01 (ANOVA). 
Bars: (B, F, and H) 100 µm; (C, E, and I) 50 µm; (D) 500 µm.
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Nuclear FGFR1 is involved in 
transcriptional regulation of target genes
Eight potential FGFR1 target genes were determined by chro-
matin immunoprecipitation (ChIP) on chip analysis of MCF-7 
cells using an anti-FGFR1 antibody (Fig. S4 B). Each gene was 
present in at least three of eight FGFR1 ChIP on chip datasets 
and not present in any of five IgG controls. Whole-cell extracts, 
as well as samples immunoprecipitated with RNA polymerase II 
antibody, were used as positive controls. Because MARK3 was 
not amplified in our repeat samples, we did not investigate it 
further. STAC3 showed strong amplification, so despite one of 
the five IgG samples showing putative binding, we decided to 
continue studying it. Primers for the promoter region of glyc-
eraldehyde 3-phosphate dehydrogenase (GAPDH) were used as 
a negative control for the samples immunoprecipitated with 
FGFR1 and IgG because it was not present as a putative target 
in any of our ChIP on chip datasets (Fig. S4 B).
Putative FGFR1 target genes identified by ChIP on chip 
were analyzed by real-time RT-PCR expression analysis after 
RNAi-mediated FGFR1 knockdown (Fig. S1) or transient 
overexpression of FGFR1b (Fig. S5, A–C). FGFR1b over-
expression was confirmed by real-time RT-PCR (Fig. S5 A) 
and by immunofluorescence using an anti-FGFR1 antibody 
(Fig. S5 B). Western blotting with an anti-FGFR1 antibody 
also showed a significant increase in FGFR1 protein (Fig. S5 C). 
Both full-length FGFR1 and cleaved FGFR1 were up-regulated 
48 h after transfection (sixfold and 2.5-fold increase, respec-
tively; Fig. S5 C).
Table 1 shows changes in target gene mRNA expression 
in MCF-7 cells after FGFR1b overexpression or FGFR1 knock-
down (both at 48 h). Data presented are normalized to GAPDH, 
with hypoxanthine-guanine phosphoribosyltransferase (HPRT) 
normalization giving identical results (unpublished data). 
Although levels of POU2F2 expression tended to increase upon 
either up- or down-regulation of FGFR1 expression, STAC3 
behaved in the opposite fashion, so these were not investigated 
further. However, FGFR1 acted clearly as a transcriptional repres-
sor for EBI3 and GRINA, whereas it activated expression of 
KRTAP5-6 (Keratin-associated protein 5-6), PRSS27 (also called 
Marapsin), and Stratifin (SFN).
Furthermore, RNAi-mediated knockdown of GrB led to 
up- and down-regulation of negatively and positively regulated 
FGFR1 target genes, respectively (Fig. 8). Transient over-
expression of IC-FGFR1 resulted in increased expression of 
KRTAP5-6 and PRSS27, though not all target genes showed 
significant changes in expression in these transient transfec-
tions. Expression of GrB-resistant FGFR1b VSAN did not 
affect target gene expression (Table 1).
To confirm that these FGFR1-regulated genes could con-
trol cell behavior, we performed individual RNAi-mediated 
knockdown of each of the targets in MCF-7 cells and assessed 
the subsequent impact on cell migration. All of the target 
genes showed efficient knockdown of expression at 48 h after 
RNAi transfection (Fig. 8 A), and where the antibody was 
available in house, we also confirmed knockdown at the pro-
tein level (Fig. 8 A*). Cells in which target gene expression 
had been knocked down were used subsequently in Transwell 
migration assays (Fig. 8 B). Knockdown of mRNA for each of 
the target genes up-regulated by FGFR1 (KRTAP5-6, SFN, 
and PRSS27) resulted in significantly decreased MCF-7 cell 
migration, whereas migration was increased after knockdown 
of mRNA for the target genes down-regulated by FGFR1 
(GRINA and EBI3). The reduction in migration after KRTAP5-6, 
SFN, and PRSS27 knockdown was identical to that seen 
when FGFR1 was targeted, and compound knockdown of all 
three FGFR1 up-regulated targets, with or without concomi-
tant knockdown of FGFR1, produced no further reduction in 
cell migration (Fig. 8 B).
Discussion
FGFR signaling plays critical roles during embryogenesis and, 
in the adult, regulating a wide range of cell behaviors, including 
proliferation, migration, survival, and differentiation. Such a 
mechanism is highly susceptible to hijacking by cancer cells 
seeking to gain a growth advantage. Indeed, the link between 
aberrant FGFR signaling and developmental abnormalities and 
tumorigenesis is unequivocal (Turner and Grose, 2010). Ampli-
fications of both FGFR1 and FGFR2 are reported in ≤10% of 
breast cancer patients, and at least for FGFR1, amplification 
is associated with a poorer outcome (Reis-Filho et al., 2006; 
Elbauomy Elsheikh et al., 2007). In particular, amplification 
and subsequent overexpression of FGFR1 contributes to poor 
prognosis in luminal-type breast cancers, driving endocrine 
Table 1. Regulation of FGFR1 target genes
Gene FGFR1b-VSAD FGFR1 RNAi FGFR1b-VSAN
 Fold change P-value Fold change P-value Fold change P-value
EBI3 0.25 ± 0.02 <0.001 1.93 ± 0.26 <0.05 1.07 ± 0.39 NS
GRINA 0.7 ± 0.14 <0.05 7.38 ± 5.5 NS 1.55 ± 0.57 NS
KRTAP5-6 4.25 ± 1.66 NS 0.27 ± 0.05 <0.01 0.77 ± 0.27 NS
POU2F2 2.42 ± 1.3 NS 1.34 ± 0.35 NS  
PRSS27 3.25 ± 1.6 NS 0.31 ± 0.05 <0.01 1.53 ± 0.63 NS
SFN 3.76 ± 1.56 <0.05 0.57 ± 0.11 <0.05 1.17 ± 0.26 NS
STAC3 0.75 ± 0.13 <0.05 0.5 ± 0.12 <0.01  
Fold change of mRNA expression in MCF-7 cells of genes identified after ChIP on chip with an anti-FGFR1 antibody, after 48-h overexpression of WT (VSAD) FGFR1b, 
48-h RNAi of FGFR1, or 48-h overexpression of GrB-resistant (VSAN) FGFR1b. Real-time PCR was analyzed using the 2Ct method and using expression of HPRT 
and GAPDH as housekeeping genes for normalization. Data presented in the table are normalized with GAPDH. n ≥ 3 independent experiments in triplicate. Minus 
signs indicate where analysis was not performed. Statistical significance was tested with both Mann–Whitney and Student’s t test.
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Loeb et al., 2006) but not in the context of nuclear trafficking. 
First described as a target for MMP-2 (Levi et al., 1996), the focus 
was on the proteolytic shedding of FGFR1 and its potential 
functional effects (Hanneken, 2001) rather than what happened 
to the intracellular portion of the receptor. A later study identi-
fied FGFR1 as a substrate for the serine protease GrB, but the 
context again was different, with cleavage of FGFR1 thought to 
prevent survival signaling caused by cleavage between the ligand 
binding and tyrosine kinase domains (Loeb et al., 2006). Most 
interestingly, this latter study reported that cleavage by GrB 
generated a 55–60-kD C-terminal receptor fragment. The cleavage 
site for GrB is unique to FGFR1 among the FGFRs.
Having determined that our breast cancer cell lines ex-
pressed GrB, we investigated whether endogenous GrB was 
mediating cleavage of FGFR1 in a fashion similar to the way 
that exogenous GrB was shown to cleave FGFR1 in prostate 
cancer cells (Loeb et al., 2006). Treatment with a GrB synthetic 
peptide inhibitor (Martin et al., 1998), a serine protease inhibi-
tor, DCI (Harper et al., 1985), or with RNAi to GrB led to sig-
nificant reductions in FGFR1 nuclear localization (Fig. 3 and 
Fig. 4), suggesting that GrB indeed plays an important role in 
the process. Treatment with the GrB inhibitor increased levels 
of full-length FGFR1 (Fig. 3 C), indicating that GrB might be 
involved in receptor turnover. Importantly, inhibition of GrB 
blocked accumulation of nuclear FGFR1 after FGF-10 treat-
ment (Fig. 4, B and C) and, at a functional level, blocked the 
promigratory effect of FGF-10 treatment (Fig. 4 D and Fig. S2, 
B and C). These data suggested that activation of the classical 
FGFR1 signaling cascade alone was not sufficient to drive cell 
migration but that nuclear localization of the receptor may also 
be critical. The effect of GrB inhibition clearly did not affect 
solely FGFR1 because the inhibition of baseline migration in 
unstimulated cells was impaired significantly when cells were 
therapy resistance (Turner et al., 2010). Indeed, FGFR1 ampli-
fication is the strongest independent predictor of poor outcome 
in patients with ER-positive tumors (Elbauomy Elsheikh et al., 
2007). However, despite many studies, the mechanism by which 
FGFR signaling might control metastatic cell behavior and con-
tribute to cancer progression is far from clear. Our study identi-
fies a novel mechanism by which FGFR1 signaling regulates 
cancer cell behavior.
Upon ligand binding, FGFRs are known to activate 
several downstream signaling pathways, including PI3K, 
PLC-, and MAPK (Ornitz and Itoh, 2001). We focused on 
the ER-positive MCF-7 breast cancer cell line, which activates 
the MAPK signaling pathway rapidly upon FGF-10 stimula-
tion. As expected, this was abrogated by pretreatment with a 
specific inhibitor for FGFR (PD173074; Fig. 1 A; Mohammadi 
et al., 1998).
Having confirmed that FGFR signaling was eliciting 
the anticipated functional effects in cells, we focused specifi-
cally on FGFR1, investigating the subcellular trafficking of 
the receptor after ligand binding. Using recombinant FGF-10 
as a known ligand of FGFR1b (Zhang et al., 2006), we ob-
served a dramatic localization of FGFR1 to the nucleus after 
receptor activation (Fig. 2 A and Fig. S1) and showed that 
a 55–60-kD C-terminal portion of the receptor accumulated 
in the nucleus (Fig. 2 B).
Several studies have reported nuclear localization of full-
length FGFRs (Maher, 1996; Stachowiak et al., 1996a,b; Reilly 
and Maher, 2001; Zammit et al., 2001; Peng et al., 2002; Myers 
et al., 2003; Reilly et al., 2004; Dunham-Ems et al., 2009), but 
in contrast to other RTKs (Carpenter and Liao, 2009), there has 
been no evidence in the literature for receptor cleavage being 
implicated in nuclear translocation. Cleavage of FGFR1 has 
been reported previously (Levi et al., 1996; Hanneken, 2001; 
Figure 8. Down-regulation of FGFR1 target genes by RNAi had an effect on cell migration. (A and B) Transwell migration assay showed that after 48-h 
RNAi treatment of KRTAP5-6, Stratifin (SFN), and PRSS27, MCF-7 cells migrated less compared with control cells (scrambled [Scr] RNAi treated). However, 
48-h RNAi treatment of GRINA and EBI3 genes increased cell migration. *, P ≤ 0.05; **, P < 0.01; ***, P < 0.001 (paired Student’s t test). Error bars 
show means ± SEM. Ctr, control; KRT, keratin; PRS, PRSS27.
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conditions, but this effect was blocked completely when cleavage 
of the receptor was prevented by GrB inhibition (Fig. 6).
Having confirmed that nuclear localization of FGFR1 
was critical for migration of breast cancer cells in 2D culture, 
we determined the expression pattern of FGFR1 in a more 
physiological 3D model (Fig. 7). FGFR1 was localized to the 
nucleus specifically in breast cancer cells that invaded into the 
stroma, and this invasion was impaired significantly by block-
ing FGFR signaling. Most interestingly, when we analyzed 
expression of FGFR1 in samples of human invasive breast 
cancer, we saw clear nuclear localization of FGFR1 in invad-
ing cells (Fig. 7, H and I). Nuclear localization of RTKs has 
been implicated in poor prognosis in a variety of studies (Zammit 
et al., 2001; Adam et al., 2003; Lo et al., 2005b; Li et al., 2009a; 
Xia et al., 2009). Collectively, our findings suggest that local-
ization of FGFR1 to the nucleus may be critical to cell migra-
tion and invasion.
There is strong evidence that RTKs can act to regulate 
transcription of target genes in the nucleus (Xie and Hung, 
1994; Lin et al., 2001; Wang et al., 2004; Lo et al., 2005a) and 
increasing data supporting a possible regulatory role for FGFR1 
(Peng et al., 2002; Hu et al., 2004; Fang et al., 2005; Dunham-
Ems et al., 2009). We identified several putative target genes for 
nuclear FGFR1 (Fig. S4 B and Table 1), the detailed study of 
which is the subject of ongoing studies. Of the three genes iden-
tified as being positively regulated by FGFR1, all have potential 
links with invasive cell behavior. PRSS27 is overexpressed in 
pancreatic cancer (Badea et al., 2008) as well as in hyperprolif-
erative keratinocytes (Li et al., 2009b), SFN has been impli-
cated in malignant lung cancer (Shiba-Ishii et al., 2011), and 
although the function of KRTAP5-6 is unknown, Keratin 6 is 
well documented as a marker of proliferative and migratory 
keratinocytes (Navarro et al., 1995). Less is known about a 
possible role in cancer for the two genes that were negatively 
regulated by FGFR1, EBI3 (Devergne et al., 1996) and GRINA 
(Kumar et al., 1991). However, our ChIP data, together with 
modulation of FGFR1 levels in MCF-7 cells, either through 
overexpression or RNAi-mediated knockdown of the receptor 
coupled with GrB inhibition, showed that FGFR1 has a clear 
potential to regulate transcription of target genes, either directly 
or as part of a larger complex.
The functional relevance of these target genes was con-
firmed by RNAi-mediated knockdown experiments. All three 
genes identified as targets for up-regulation by FGFR1, 
KRTAP5-6, SFN, and PRSS27, were found to regulate MCF-7 
cell migration positively. Conversely, targets that were nega-
tively regulated by FGFR1, GRINA and EBI3, were found to in-
hibit cell migration (Fig. 8 B). Collectively, these observations 
support the hypothesis that nuclear FGFR1 might regulate an 
invasive gene expression signature. Interestingly, compound 
knockdown of all the promigratory target genes resulted in no 
additive impairment of migration, suggesting that the genes 
might lie in the same pathway.
Although studies of GrB function focus largely on cyto-
toxic lymphocytes and its induction of apoptosis in target 
cells, GrB expression has been observed in a range of cell 
types, including urothelial cancer cells (D’Eliseo et al., 2010) 
treated with GrB inhibitor (Fig. 4 D) compared with the spe-
cific FGFR inhibitor PD173074 (Fig. 1 B). Indeed, the peptide 
inhibitor is known to also inhibit Caspase 8 (Thornberry et al., 
1997). However, cells treated with GrB inhibitor were still 
capable of mounting a significant migratory response after treat-
ment with EGF, a known motogenic stimulus (Xie et al., 1995). 
Critically, this confirmed that the antimigratory effect of GrB 
inhibition was not simply the result of a catastrophic effect on 
cell viability.
Further evidence that GrB activity was induced in serum-
starved MCF-7 cells upon FGF-10 treatment was provided by 
in vitro GrB activity assay. The significant increase in GrB 
activity seen after FGF-10 stimulation was blocked completely 
by treatment with the serine protease inhibitor DCI (Fig. 4 E). 
Indeed, MCF-7 cells growing in complete medium showed 
significant GrB activity that was blocked by treatment with 
DCI (Fig. 4 F). Because DCI treatment blocks granzyme but 
not caspase activity, these data suggest that, in our activity assay, 
substrate cleavage was dependent on the serine protease GrB and 
not affected by Caspase 8, which can cleave the Ac-IEPD-pNA 
substrate (Thornberry et al., 1997). Together with the findings 
that either DCI treatment (Fig. 4 G) or RNAi-mediated knock-
down of GrB (Fig. 3) decreased levels of cleaved nuclear 
FGFR1, our data strongly support the hypothesis that FGF-10 
treatment increases nuclear FGFR1 via GrB-mediated cleavage 
(Fig. 2 and Fig. 4, B and G).
Interestingly, an antibody recognizing a juxtamembrane 
region of FGFR1, N terminal to the GrB cleavage site, also 
showed positive FGFR1 nuclear staining, suggesting that the 
N-terminal fragment of the receptor also enters the nucleus. 
Unfortunately, the antibody did not work on Western blots, so this 
could not be confirmed by cell fractionation, but the lack of full-
length FGFR1 in the nuclear fraction, seen when we blotted 
with our C-terminal antibody, suggested that the N-terminal 
staining must represent a cleaved portion of the receptor.
To confirm the significance of GrB-mediated cleavage 
of FGFR1, we mutated the GrB cleavage site of the full-length 
human FGFR1b (Fig. 5 A) as described previously (Loeb et al., 
2006). Immunofluorescent staining for FGFR1 revealed that 
MCF-7 cells transfected either with WT or cleavage-resistant 
full-length FGFR1 expressed high levels of FGFR1 protein 
(Fig. 5 B). However, although the WT receptor was seen clearly 
in the nucleus, cells transfected with the mutant receptor showed 
no more nuclear FGFR1 than empty vector–transfected cells. 
When the functional significance of this finding was tested by 
assaying migration in the presence or absence of FGF-10, cells 
transfected with WT FGFR1 showed a significant increase in 
migration both in unstimulated and stimulated conditions, when 
compared with control cells (Fig. 5 B). In contrast, cells trans-
fected with mutant FGFR1 showed no increase in their migra-
tory capacity, indicating that cleavage and nuclear trafficking 
of FGFR1 is critical to its promigratory effect. These data were 
reinforced by the finding that cells transfected with a construct 
expressing the cleaved intracellular portion of FGFR1 showed 
enhanced migratory potential, even in the presence of a GrB 
inhibitor. In contrast, cells expressing a full-length FGFR1 
construct displayed enhanced migration under normal culture 
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and reverse, 5-CGAACAGGAGGAGCAGAGAGCGA-3; GAPDH for-
ward, 5-CAATGACCCCTTCATTGACC-3, and reverse, 5-TTGATTTT-
GGAGGGATCTCG-3; GRINA (promoter sequence) forward, 5-TGAAG-
CCGCTGAGGTTAAGT-3, and reverse, 5-GTGCGACACTGACAGG-
AGAA-3; GRINA forward, 5-GCTCTTCATCTTCGCCATTC-3, and reverse, 
5-CAGCGCAGCAAACACATACT-3; HPRT forward, 5-GACCAGTCAA-
CAGGGGACAT-3, and reverse, 5-CCTGACCAAGGAAAGCAAAG-3; 
KRTAP5-6 (promoter sequence; Ta, 62°C) forward, 5-GCCTAGCGAGA-
AGTGACAGG-3, and reverse, 5-ATGAGCGGTTTGTCTCTGGT-3; 
KRTAP5-6 forward, 5-AGCCCTGCTACTGTTCCTCA-3, and reverse, 
5-GGACTCACCTGAGGTCCAAA-3; MARK3 (promoter sequence) for-
ward, 5-CTCCCTGCTCCTGAATCTTG-3, and reverse, 5-CATGATGCCC-
ATTCACTCTG-3; MARK3 forward, 5-TCCTGTGCAGATGAACAACC-3, 
and reverse, 5-ATTGCAACCTCTCTGCCTGT-3; POU2F2 (promoter se-
quence) forward, 5-TGAGCTTCCCTGTCATTTCC-3, and reverse, 5-GAA-
GGGAGGAGGATTTGGAG-3; POU2F forward, 5-CCTGCTCAGTTCCT-
GCTACC-3, and reverse, 5-TCCAGCTCCTCCAGATCACT-3; PRSS27 (pro-
moter sequence; Ta, 55°C) forward, 5-TTTGAACAGAACTGCGGATG-3, 
and reverse, 5-TGGGAGTCTTCCCCCTCTAT-3; PRSS27 forward, 5-CTTT-
GAGACGGGCATGAACT-3, and reverse, 5-CCAAACTCGGTGTCTTT-
GCT-3; SFN (promoter sequence; Ta, 62°C) forward, 5-GCCAGGCT-
GATCTCAAACTC-3, and reverse, 5-GCTGAGAGGGAACAGCAATC-3; 
SFN forward, 5-GTCTGATCCAGAAGGCCAAG-3, and reverse, 5-TGAGA-
GCAGGTTTCGCTCTT-3; STAC3 (promoter sequence) forward, 5-ACCC-
AACTTGCATCTGCTTC-3, and reverse, 5-ATGCCACAGTCATGGAGTCA-3; 
and STAC3 forward, 5-GGGCTTCGCTGTAAGAACTG-3, and reverse, 
5-GCGTACTGCTGGTTGCTGTA-3.
Western blotting
Cell lysates were prepared using radioimmunoprecipitation assay buffer 
(Millipore) containing 1 mM NaF, 1 µg/ml aprotinin, 1 µg/ml leupeptin, 
1 µg/ml pepstatin, and 1 mM PMSF (all obtained from Sigma-Aldrich), 
and the protein yield was determined using a Bradford dye binding assay 
(Bio-Rad Laboratories). Equivalent amounts of protein from different lysate 
samples (60 µg/well) were resolved by gel electrophoresis using precast 
4–12% Bis-Tris mini gels (NuPAGE Novex; Invitrogen). After transferring 
proteins onto a nitrocellulose membrane (Whatman) overnight at 4°C at 
12 V, membranes were blocked for 1 h at RT in 5% milk/PBS. Primary anti-
bodies were diluted in 3% BSA/PBS and incubated overnight at 4°C. All 
antibodies were rabbit polyclonal unless otherwise stated: anti–-tubulin 
antibody (mouse monoclonal; 1:2,000; Sigma-Aldrich), anti-Akt1/PKB- 
(1:1,000; Millipore), anti-BIP/GRP78 (mouse monoclonal; 1:1,000; BD), 
anti–Cathepsin C (mouse monoclonal; D-6; 1:600; Santa Cruz Biotechnology, 
Inc.), anti-FGFR1 (1:1,000; SC-121; Santa Cruz Biotechnology, Inc.), 
anti-GrB antibody (1:1,000; Cell Signaling Technology), anti–HSC-70 
(mouse monoclonal; 1:2,000; Santa Cruz Biotechnology, Inc.), anti–Lamin 
A/C (goat polyclonal; 1:600; sc-6215; Santa Cruz Biotechnology, Inc.), 
anti-MAPK1/2 (mouse monoclonal; 1:1,000; Millipore), anti-pAkt 
(1:1,000; Cell Signaling Technology), anti-pFRS2(Tyr196) (1:1,000; Cell 
Signaling Technology), anti-pERK (1:1,000; Cell Signaling Technology), 
anti–PLC-1 (1:1,000; Cell Signaling Technology), anti–pPLC-1 
(1:1,000; Cell Signaling Technology), and anti-TOPOII (1:1,000; Santa 
Cruz Biotechnology, Inc.).
All secondary antibodies conjugated with HRP were obtained from 
Dako, and they were diluted in 3% BSA/PBS. Blots were incubated for 1 h 
at RT and were developed with ECL (GE Healthcare). All washes after the 
primary and the secondary antibodies were performed in 0.1% Tween 
20/PBS for 3× for 5 min. Densitometric analysis was performed using 
ImageJ 1.429 software (National Institutes of Health). Signal density was 
normalized to the anti–-tubulin or anti-HSC70 antibody as a loading con-
trol/reference for at least three separate treatments.
Migration assay
105 cells were plated onto 8-µm-pore Transwell migration filters in 24-well 
plates (Corning). Cells transfected with FGF-10 or empty vector were 
used 48 h after transfection. Cells were incubated either in DME supple-
mented with 4 mM l-glutamine and 1–10% FBS gradient or in DME supple-
mented with 0.1% BSA and with 4 mM l-glutamine without FBS overnight 
(12 h). The bottom of the Transwell was coated with 10 µg/ml fibronectin 
(Sigma-Aldrich) for 1 h at 37°C before plating the cells. 100 ng/ml 
FGF-10 (+300 ng/ml heparin) or 10 ng/ml EGF (Sigma-Aldrich) was 
added to the bottom of the Transwell as necessary. In the case of GrB 
inhibition, cells were pretreated with 25 µM GrB inhibitor before the 
migration assay as well as during (both in the top and bottom compart-
ment of the Transwell) for 24 h in total.
and breast cancer cells (Hu et al., 2003). Notably, in urothelial 
cancer, expression of GrB was concentrated at the cancer inva-
sion front (D’Eliseo et al., 2010). There is evidence that GrB 
plays a role in extracellular proteolysis (Buzza et al., 2005), 
though the literature is divided as to whether this activity is 
pro- or antiinvasive. Our data show clearly that endogenous 
GrB can play a promigratory role, at least in part through 
cleaving FGFR1.
Further studies into determining where in the cell receptor 
cleavage occurs are ongoing in the laboratory, and detailed traf-
ficking studies hopefully will clarify which are the key cellular 
compartments in the trafficking process. Cathepsin C is known 
to be an activator of GrB (Pham and Ley, 1999), and the activa-
tion of Cathepsin C in MCF-7 cells after FGF-10 treatment 
(Fig. S4 A) fits well into our model. Although there are many 
future questions to be answered, including whether there is a 
functional nuclear localization signal in FGFR1, we have iden-
tified an entirely novel mechanism by which FGF signaling 
may regulate cancer cell behavior. Establishing the functional, 
prognostic, and therapeutic relevance of this new pathway in 
FGF signaling may prove critical for the development of new 
targeting strategies.
Materials and methods
Cell culture
MDA-MB-231 and MCF-7 cells were grown in DME without phenol red 
(Sigma-Aldrich) supplemented with 10% FBS (Biosera) and 4 mM l-glutamine 
(Cancer Research UK London Research Institute Cell Services). All cells were 
incubated at 37°C, 8% CO2, and 100% relative humidity.
FGF-10 stimulation and inhibitor treatments
Cells (MDA-MB-231 or MCF-7) were seeded in DME without phenol red 
(with 10% FBS) either in 6-well plates (for protein extraction) or in 24-well 
plates (for immunocytochemistry) with 18-mm2 coverslips (VWR Interna-
tional). The next day, medium was removed and replaced with serum-free 
medium containing 0.1% BSA (Sigma-Aldrich). Cells, at 70% confluency, 
were serum-starved overnight. For inhibitor experiments, cells were 
treated for 1 h with the FGFR inhibitor PD173074 (2 µM; Sigma-Aldrich) 
before stimulation with 100 ng/ml FGF-10 (PeproTech) and 300 ng/ml 
heparin sodium salt (Sigma-Aldrich) for different time points depending 
on the experiment.
RT-PCR and real-time RT-PCR
Extraction of total RNA was performed using an RNeasy kit (QIAGEN). All 
samples were treated with DNase on spin columns. Synthesis of cDNA was 
performed using reverse transcription (Superscript II; Invitrogen). RT-PCR 
was performed using PCR mastermix (MegaMix blue; Cambio). Real-time 
RT-PCR was performed using SYBR green RT-PCR kit (QuantiTect; QIAGEN) 
and using expression of HPRT and GAPDH as housekeeping genes for nor-
malization with a melting curve performed after each reaction.
Primers for the promoter region of genes identified by ChIP on chip 
were designed using the sequences from the peak from the chip analysis 
after ChIP with FGFR1 antibody (Santa Cruz Biotechnology, Inc.). See next 
paragraph for primer pairs used for PCR and real-time RT-PCR. For Real-
time RT-PCR, the threshold amplification cycles were determined using a 
real-time PCR machine (StepOnePlus; Applied Biosystems) and analyzed 
by the 2Ct method (Livak and Schmittgen, 2001).
The following primer pairs were used for PCR and real-time RT-PCR 
(annealing temperature [Ta] for all primers was 60°C unless otherwise 
stated): EBI3 (promoter sequence) forward, 5-GGGAGAGGGGAACAG-
AAAAA-3, and reverse, 5-CCTCTCCCTGTTCTTGCAACT-3; EBI3 forward, 
5-ATTGCAACCTCTCTGCCTGT-3, and reverse, 5-CGGTGACATTGA-
GCACGTAG-3; FGF-10 forward, 5-ATGTCCGCTGGAGAAAGCTA-3, 
and reverse, 5-CCTCTCCTTGGAGCTCCTTT-3; FGFR1b forward, 5-TTAATA-
GCTCGGATGCGGAG-3, and reverse, 5-ACGCAGACTGGTTAGCTTCA-3; 
GAPDH (promoter sequence) forward, 5-TACTAGCGGTTTTACGGGCG-3, 
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thoroughly in PBS, bisected, and dehydrated through a graded ethanol 
series before wax embedding.
Immunofluorescence of OCs for optical projection tomography
OCs were fixed in 4% PFA overnight at 4°C and then washed for 30 min 
in PBS. Samples were dehydrated stepwise in methanol with PBS diluent 
(33, 66, and 100% methanol for ≥15 min at each step). The samples 
were incubated at 80°C three to five times for ≥1 h each time and 
back to RT to ensure that antigens in the deeper parts of the tissue were 
rendered accessible. Tissues were then rehydrated in a series of 0.1% 
Tween 20/PBS (PBST) with methanol as diluent (33, 66, and 100% for 
15 min at each step). Tissues were blocked in 10% BSA/PBS for 24 h 
at 4°C and then incubated with primary antibody (rabbit anti-NESO at 
1:100 dilution) and diluted in 1.5 ml blocking solution containing 5% 
DMSO for 48 h at 4°C. After 4× 30-min washes with PBST, samples 
were incubated with secondary antibody (1:100; goat anti–rabbit Alexa 
Fluor 488 antibody; Invitrogen) and diluted in 1.5 ml blocking solution 
containing 5% DMSO for 48 h at 4°C followed by washing with PBST 
4× for 30 min. Finally, samples were fixed in 4% PFA overnight at 4°C 
and then washed in PBST 5× for 30 min. The samples were then sent to 
Bioptonics (Medical Research Council Technology) for optical projec-
tion tomography.
Subcellular fractionation
MCF-7 and MDA-MB-231 cells were plated in T25 flasks (VWR Interna-
tional), and subcellular fractionation was performed using a subcellular 
protein fractionation kit (PerkinElmer). In the case of FGF-10 and/or GrB 
treatment, fractionation was performed using a different kit (Universal 
Magnetic Co-IP kit; Active Motif) because of the discontinuation of the pre-
vious kit.
GrB inhibitor treatment
5 × 104 cells were plated in a 24-well plate in DME supplemented with 4 mM 
l-glutamine and 10% FBS. The next day, cells were treated with 25 or 50 µM 
GrB synthetic peptide inhibitor (Caspase-8 inhibitor II; EMD; Martin et al., 
1998) for 12, 24, and 48 h and then fixed with 4% PFA for subsequent stain-
ing for FGFR1. In the case of cotreatment with FGF-10/heparin, cells were 
treated with 25 µM GrB inhibitor for 24 h in DME supplemented with 4 mM 
l-glutamine and 0.1% BSA. After 24 h of treatment, FGF-10 was added as 
described previously in this paper for 1–2 h. Alternatively, MCF-7 cells were 
treated for 5 h with 50 µM DCI (Enzo Life Sciences), a serine protease inhibitor 
(Harper et al., 1985), and then fixed as described previously in this paper.
RNAi
siRNA used (Thermo Fisher Scientific) were as follows: Genome SMART-
pool for human FGFR1 (M-003131) and human GrB (M-005889). For silenc-
ing FGFR1 target genes, the following ON-TARGETplus siRNA SMARTpools 
were used: human PRSS27 (L-005971), human SFN (L-005180), human 
GRINA (L-010697), human EBI3 (L-012093), and human KRTAP5-6 
(L-033250). Cells (40–50% confluent in 6-well plates) were transfected for 
4 h with 10 nM siRNA using 4 µl INTERFERin (Polyplus Transfection; 
PeqLab) in a total reaction volume of 1.1 ml in each well of a 6-well plate. 
mRNAs, proteins, and functional activity were assayed 48–72 h after 
transfection and compared with mock and/or control siRNA-treated cells 
(siCONTROL Non-Targeting siRNA pool D-001210 or ON-TARGETplus 
Non-Targeting Pool D-001810; Thermo Fisher Scientific). Transfection 
efficiency was assessed independently using a positive control siRNA 
Lamin A/C (D-001050; Thermo Fisher Scientific), which was compared 
with the siCONTROL nontargeting siRNA.
Cloning FGFR1b and IC-FGFR1b
Full-length human FGFR1b cloned into SalI and BamHI sites of the pBlue-
script KS II (+) vector was a gift from S. Werner (Eidgenössische Tech-
nische Hochschule Zürich, Zürich, Switzerland). Full-length human 
FGFR1b was subcloned into the BamHI and XhoI sites of the pcDNA4/
TO mammalian expression vector (Invitrogen).
The IC-FGFR1 was amplified from our full-length FGFR1b construct 
using cloning PCR primers tagged with c-MYC epitope and containing 
engineered EcoRI and HindIII recognition sites. The PCR product was 
cloned into the HindIII and EcoRI sites of pcDNA4/TO. The following 
sequences were used: hFGFR1-IC forward, 5-CACAAGCTTAAGAT-
GAAGAGTGGTACCAAGAAGAGTGACTTCCACAGCC-3, and hFGFR1-full 
length reverse c-MYC tag, 5GCCGAATTCTCACAGATCTTCTTCAGA-
AATAAGTTTTTGTTCGCGGCGTTTGAGTCCGCCATTGGC-3. Cells were 
transfected with 1 µg DNA using 3 µl Lipofectamine 2000 (Invitrogen) for 4 h.
Cells treated with siRNA were used 48 h after transfection. The cells 
were plated in serum-free medium with 0.1% BSA and with medium con-
taining 10% FBS at the bottom of the Transwell. The bottom of the Transwell 
was coated with fibronectin as described previously in this paper.
Cells that had migrated to the lower surface were trypsinized. Simi-
larly, cells from the upper chamber, which had not migrated, were re-
moved with a cotton bud or trypsinized and counted separately. When 
treatments had an effect on cell number during the course of the migration 
assay (as a result of changes in either apoptosis and/or proliferation), the 
percentage of cell migration was calculated by normalizing the number of 
cells that migrated through the Transwell to the total cell number in the 
upper and lower chambers. The cell number was determined using an 
automatic cell counter (CASY; Schärfe System).
Proliferation assay
5 × 104 cells were plated in a 24-well plate in DME supplemented with 
4 mM l-glutamine and 0.1% BSA with or without the presence of 100 ng/ml 
FGF-10 (and 300 ng/ml heparin). Cells were trypsinized and counted after 
12, 24, and 48 h as described previously in this paper.
Immunofluorescence
All materials were obtained from Sigma-Aldrich unless otherwise stated. 
Cells on coverslips were fixed in 4% PFA in PBS for 15–20 min at RT and 
washed 3× for 5 min in PBS. Cells were permeabilized in 0.1% saponin/PBS 
at RT for 10 min and washed once with PBS. After blocking for 1 h at RT 
with 5% BSA/PBS, cells were incubated with primary antibody diluted 
in 3% BSA/PBS for 1 h at RT.
After incubation with primary antibody, cells were washed 3× for 
5 min in PBS and then incubated with a secondary antibody conjugated 
with FITC (goat anti–rabbit IgG (H+L)-FITC; 1:100; Invitrogen) or Cy3 (donkey 
anti–mouse IgG-Cy3; 1:500; Jackson ImmunoResearch Laboratories, Inc.; 
Stratech Scientific) and diluted in 3% BSA/PBS for 1 h at RT. Finally, cells 
were washed again in PBS 3× for 5 min, and a final wash with H2O was 
performed before mounting on slides using aqueous mounting media con-
taining DAPI (Vectashield; Vector Laboratories).
For OCs, 4-µm paraffin sections were first dewaxed in xylene, rehy-
drated through a graded ethanol series, and collected in PBS followed by 
microwaving (900 W) in 10 mM sodium citrate buffer, pH 6.0, for 20 min. 
Sections were washed three times with PBS for 1 min each. Subsequent 
staining was performed as described previously in this paper.
Primary antibodies used were as follows: anti–-tubulin (mouse; 
1:2,000; reactivity: mouse and human; Sigma-Aldrich), anti–FGF-10 (goat; 
1:1,000; Abcam), anti-FGFR1 (rabbit; 1:100; ab10646; Abcam), anti-
FGFR1 (rabbit; 1:100; SC-121), anti-GrB (monoclonal mouse; 1:40; 
Novocastra Laboratories), anti-Ki67 (rabbit; 1:100; Abcam), and anti-
NESO (rabbit; 1:100; gift from M. Djamgoz, Imperial College London, 
London, England, UK).
OC
This was modified from previously published protocols (Nyström et al., 
2005; Chioni et al., 2010). 3.48 mg/ml collagen type I (Millipore) and 
Matrigel (BD) were mixed in a ratio of 70:30 (80% of final gel volume), 
10× Hank’s buffer (10% final gel volume) was added to the mix, and pH 
was adjusted to 7.4 with 2 M NaOH. Human foreskin fibroblasts (American 
Type Culture Collection) were resuspended in FBS (10% final gel volume) 
at 5 × 105/ml and added to the mix. The final mixture was applied to a 
24-well plate (1 ml/well) and incubated at 37°C and 8% CO2 for 4 h, after 
which the gels were equilibrated by immersion in medium for 16 h, where-
upon the medium was replaced by 500 µl culture medium containing 106 
MDA-MB-231 cells. 250 µl collagen mix (7 vol collagen type I, 1 vol each 
of 10× Hank’s buffer, FBS, and culture medium neutralized with 2 M 
NaOH) was added dropwise onto 400-mm2 Nylon membranes (100-µm 
pore; Tetko, Inc.). Membranes were incubated at 37°C for 30 min and 
then fixed for 1 h at 4°C with 1% glutaraldehyde (Sigma-Aldrich)/PBS. After 
fixation, the membranes were washed 4× for 5 min in PBS and incubated 
overnight in culture medium at 4°C. The coated membranes were placed 
on 25-mm2 sterile stainless steel grids in 6-well plates. Gels were lifted from 
the 24-well plate and laid on top of the coated membranes. An appropri-
ate amount of culture medium was added to each well until it reached the 
lower part of the gel, so that the cultures were maintained at the air–liquid 
interface. In the case of treatment with 2 µM PD173074 inhibitor, fresh 
inhibitor was added to the medium at each medium change. In all cases, 
medium was changed every 2 d, and after 10 d, the gels were fixed in 4% 
PFA (Sigma-Aldrich) for 16 h at 4°C. After fixation, gels were washed 
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cycle: 95°C for 3 min, 20 cycles of 94°C for 15 s, 65°C for 5 min, and 
then a final hold at 4°C. Samples were purified using PCR clean up col-
umns (QIAquick; QIAGEN). A second amplification step was performed 
using 15 ng of purified amplified product, as described previously in this 
paper, for a further 20 cycles. Samples were then sent to NimbleGen 
(Roche) for chip analysis. An initial selection of putative targets was 
made by grouping the Excel (Microsoft) datasets returned from Nimble-
Gen. Samples, which appeared in at least three of the FGFR1 samples 
and none of the IgG controls, were considered for further analysis.
GrB activity assay
GrB activity was assayed using the chromogenic substrate Ac-IEPD-pNA 
(Enzo Life Sciences) to directly measure GrB activity in cell lysates. As a 
positive control experiment, recombinant human GrB (Enzo Life Sciences) 
was added to the reaction buffer at 3, 6, and 12 U/µl according to the 
manufacturer’s instructions. Furthermore, the serine protease inhibitor DCI 
(50 µM) was added to assay buffer together with 6 U recombinant GrB to 
confirm that it blocked GrB activity. To measure GrB activity in MCF-7 cells, 
5 × 105 cells were seeded in 6-well plates and, upon reaching 70% conflu-
ence, were serum starved overnight before treatment with 100 ng/ml FGF-10 
for the appropriate time. When appropriate, they were preincubated with 
50 µM DCI for 1 h before FGF-10 treatment. They were then lysed in 150 µl 
mammalian protein extraction reagent (Thermo Fisher Scientific) according 
to the manufacturer’s instructions. Four independent experiments were 
performed, each in triplicate using 50 µl cell lysate for each replicate. 
The colorimetric reaction was started by adding 200 µM Ac-IEPD-pNA 
substrate to each sample and monitoring absorbance at 405 nm continu-
ously in a plate reader (Spectra MR; Dynex Technologies).
Data analysis
All quantitative data are presented as means ± standard errors, unless stated 
otherwise. Statistical significance was determined with Student’s t test, Mann–
Whitney rank sum, or analysis of variance (ANOVA) test as appropriate.
Real-time PCR data were analyzed using the 2Ct method (Livak 
and Schmittgen, 2001). Results were considered significant at P < 0.05. 
Unless otherwise stated, all experiments were performed a minimum of 
three independent times each in triplicate.
Cell invasion in the OCs and nuclear staining of FGFR1 in the con-
focal images were analyzed using ImageJ 1.429 software. Cell invasion 
index was calculated using the area of the invading particles, the depth 
of invasion, and the number of invading particles. Four different OCs 
were analyzed for each condition, and each time, a whole transverse 
section through the center of the organotypic was used for analysis. To 
calculate FGFR1 staining in the nucleus, DAPI staining was used as a 
marker to define the nuclear area, and at least five random images from 
three independent experiments were analyzed.
Microscope image acquisition
Confocal images were acquired at RT using a confocal microscope 
(LSM710 Axio Observer.Z1; Carl Zeiss). Images were taken using the 
following objectives, magnifications, and numerical aperture: (a) Plan-
Apochromat, 63×, 1.40 oil differential interference contrast M27; 
(b) Plan Apochromat, 40×, 1.3 oil differential interference contrast 
M27; and (c) EC Plan Neofluar, 20×, 0.50 M27. Immersol 518 F (Carl Zeiss) 
was used as an imaging medium when required. The acquisition software 
used was ZEN 2008 (Carl Zeiss).
Bright-field images were acquired at RT using a light microscope 
(Axiophot; Carl Zeiss) connected to a camera (AxioCam HRz; Carl Zeiss). 
The objectives used were all Plan Neofluar with magnification and numerical 
aperture as follows: (a) 63×, 1.25 oil; (b) 40×, 0.75; (c) 20×, 0.5; 
(d) 10×, 0.3; and (e) 5×, 0.15. Immersol 518 F was used as an imaging 
medium when required. The acquisition software used was AxioVision 
Release 4.8 (Carl Zeiss).
Online supplemental material
Fig. S1 shows the specificity of the FGFR1 antibody that has been used 
in this study. Fig. S2 shows that GrB inhibitor treatment blocked FGFR1 
nuclear localization and RNAi-mediated knockdown of GrB reduced 
migration in MCF-7 cells. Fig. S3 shows validation of our GrB activity 
assay before assaying GrB activity in cell lysates. Fig. S4 shows effect of 
FGF-10 stimulation on Cathepsin C and GrB protein levels and validation 
of ChIP on chip results by independent ChIP. Fig. S5 confirms successful 
overexpression of FGFR1b and mRNA expression levels of FGFR1 target 
genes after RNAi-mediated knockdown of GrB or transient transfection of 
IC-FGFR1. Video 1 shows optical projection tomography of a 3D organotypic 
Site-directed mutagenesis
The mutant FGFR1b-VSAN was generated from full-length human FGFR1b 
in pcDNA4/TO using site-directed mutagenesis (QuikChange II XL; Agilent 
Technologies), the mutagenesis primer 5-CAGACAGGTAACAGTGTCT-
GCTAACTCCAGTGCATCCATGAACTC-3, and its reverse complement.
Immunohistochemistry
Paraffin-embedded sections were dewaxed in xylene and rehydrated 
through graded ethanols to PBS. Antigen retrieval was performed by micro-
waving (900 W) in 10 mM sodium citrate buffer, pH 6.0, for 20 min 
followed by 3× 1-min washes with PBS. DAB staining was performed using 
the Vectastain elite ABC kit (Vector Laboratories). In brief, samples were 
treated with hydrogen peroxide (0.3% in H2O) for 30 min at RT and then 
blocked in normal serum/PBS for 15 min at RT (150 µl FBS/10 ml PBS). 
The sections were incubated with primary antibody (in serum/PBS as 
described previously in this paper) for 1 h at RT. After washing 3× in PBS, 
they were incubated with the secondary antibody (50 µl secondary antibody 
in 10 ml serum/PBS) for 30 min at RT and washed again in PBS as pre-
viously in this paper. They were then incubated in ABC solution for 30 min 
at RT and washed 3× in PBS. The sections were then developed by using 
DAB substrate kit for peroxidase kit (Vector Laboratories) and incubated 
for 1–5 min (FGFR1 for 1 min [Abcam]; FGFR1 for 4 min [Santa Cruz 
Biotechnology, Inc.]). Sections were washed for 5 min in H2O and then 
counterstained with hematoxylin for 2 min and finally washed in tap water. 
Sections were dehydrated through graded ethanols to xylene before 
mounting in di-N-butyle phthalate in xylene (Sigma-Aldrich).
Breast human tissues were provided by L. Jones (Barts Cancer Insti-
tute, London, England, UK). Tissues from breast cancer (n = 11) and normal 
breast (n = 10) were stained for FGFR1. Primary antibodies were used as 
follows: Abcam FGFR1 (rabbit pAb; catalog no. ab10646; 1:1500) and 
Santa Cruz Biotechnology, Inc. FGFR1 (rabbit pAb Flag c-15; catalog 
no. SC-121; 1:750).
ChIP on chip analysis
ChIP (ChIP kit; Millipore) and subsequent chip analysis were performed to 
identify putative involvement of FGFR1 in transcriptional regulation. In brief, 
MCF-7 cells were used as starting material, with chromatin cross-linked by 
fixation in 1% formaldehyde for 10 min at 37°C before cell lysis. Approxi-
mately 106 cells were lysed in 200 µl SDS lysis buffer, and the DNA was 
sheared by sonication (4× 10-s sonication; 30% amplitude with 30-s break 
between each round; Vibra-Cell; Sonics and Materials, Inc.) to a mean 
length of 500 bp. The range of DNA fragment size was confirmed by 
reversing the cross-links with 8 µl of 5-M NaCl in 200 µl cell lysate at 65°C 
for 4 h, recovering the DNA by phenol/chloroform extraction, and electro-
phoresing the sample on a 1% agarose/TBE (Tris-borate-EDTA) gel. The 
sonicated cell lysate was diluted 10-fold in ChIP dilution buffer, and 1% of 
the diluted DNA was kept as the input control for subsequent PCR analysis. 
Histones were precleaned with salmon sperm DNA/protein A agarose 
50% slurry for 1 h at 4°C with agitation. Precleaned chromatin was 
immunoprecipitated with 2 µg anti-FGFR1 antibody (SC-121), anti–RNA 
polymerase II antibody (positive control; Millipore), or IgG1 control (BD) 
overnight at 4°C with constant rotation. The antibody–histone complex 
was collected by adding salmon sperm DNA/protein A agarose slurry 
(30% of the total sample volume) for 1 h at 4°C with constant rotation. The 
samples were washed and eluted. Both the immunoprecipitated and the con-
trol input samples (each in 500-µl volume) were then subjected to cross-link 
reversal, adding 10 µl of 0.5-M EDTA, 20 µl of 1-M Tris-HCl, pH 6.5, and 
2 µl of 10-mg/ml proteinase K, and incubating for 1 h at 45°C. DNA was 
recovered by phenol/chloroform extraction and ethanol precipitation.
Eight different chromatin samples were immunoprecipitated with 
FGFR1 antibody, and five were immunoprecipitated with an IgG control. 
One sample immunoprecipitated with RNA polymerase II was used as a 
positive control. Samples were amplified by whole-genome amplification 
(WGA2 kit; Sigma-Aldrich). Library preparations were performed using 
the whole chromatin immunoprecipitated sample (resuspended in 10 µl 
water). However, in the case of the input control, 10 ng of each sample 
was diluted with water to a final volume of 10 µl. In each sample, 2 µl of 
Library preparation buffer and 1 µl Library stabilization solution were 
added and incubated at 95°C for 2 min. Samples were cooled on ice and 
spun briefly, and 1 µl Library preparation enzyme was added. Samples 
were incubated as follows: at 16°C for 20 min, at 24°C for 20 min, at 
37°C for 20 min, at 75°C for 5 min, and final hold at 4°C before two 
rounds of amplification. For the first round, 7.5 µl of 10× amplification 
master mix, 47.5 µl nuclease-free water, and 5 µl WGA DNA polymerase 
was added to each tube, and samples were subjected to the following 
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